Ocumension Therapeutics has announced that the Center for Drug Evaluation of the National Medical Products Administration of China has accepted the phase III clinical trial authorization for OT-802, a self-developed product targeting presbyopia. This randomized, double-masked, placebo-controlled, parallel-group, multi-center clinical trial marks a significant step for the company in addressing the unmet needs within the presbyopia treatment market, particularly in China where no pharmaceutical treatment has been approved yet. OT-802, known as pilocarpine hydrochloride, has shown promising results in preclinical studies with rapid onset and a favorable safety profile. Ocumension also holds exclusive patent rights for the innovative dual-chamber liquid-liquid formulation technology applied to this product. The company highlights the potential commercial opportunities in this underserved market but advises shareholders and potential investors to exercise caution as the successful commercialization of OT-802 is not guaranteed.